Findings

What do systematic reviews say?

16 questions · 16 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 6.3%Low 10 · 62.5%Moderate 5 · 31.3%High 0 · 0%

Outpatient vs inpatients ‐ adults

Treatment failure · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ adults (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.23 [0.82, 1.85]
6 studies · 628 participants
Moderate

Outpatient vs inpatients ‐ children

Adverse drug reactions · Children with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in adverse drug reactions compared with inpatients ‐ children (low certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.9 [0.61, 5.98]
2 studies · 156 participants
Low

Outpatient vs inpatients ‐ children

Duration of neutropaenia (days) · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 268 participants
Moderate

Outpatient vs inpatients ‐ children

Length of hospitalisation (days) · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 119 participants
Low

Outpatient vs inpatients ‐ children

Duration of antimicrobial treatment (days) · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

Outpatient vs inpatients ‐ adults

All‐cause mortality · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.04 [0.29, 3.71]
6 studies · 628 participants
Moderate

Outpatient vs inpatients ‐ adults

Fever clearance time · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 169 participants
Low

Outpatient vs inpatients ‐ adults

Adverse drug reactions · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in adverse drugs reactions compared with inpatients ‐ adults (low certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 8.39 [0.38, 187.15]
3 studies · 375 participants
Low

Outpatient vs inpatients ‐ adults

Duration of neutropaenia (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 169 participants
Low

Outpatient vs inpatients ‐ adults

Length of hospitalisation (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 251 participants
Low

Outpatient vs inpatients ‐ children

Treatment failure · Children with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ children (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.04 [0.55, 1.99]
4 studies · 366 participants
Moderate

Outpatient vs inpatients ‐ children

All‐cause mortality · Children with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 0.63 [0.15, 2.7]
3 studies · 329 participants
Moderate

Outpatient vs inpatients ‐ children

Fever clearance time · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

Local anaesthetic infiltration (lignocaine 2%) vs Normal saline

Pain scores during procedure (VAS: 0 to 100) · women undergoing outpatient colposcopy treatment

1 finding from 1 review

Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 130 participants
Low

Local anaesthetic plus vasoconstrictor vs no analgesia

Pain scores during procedure (VAS: 0 to 100) · women undergoing outpatient colposcopy treatment

1 finding from 1 review

Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 95 participants
Low

Oral analgesia vs placebo

Pain scores during procedure (VAS: 0 to 100) · women undergoing outpatient colposcopy treatment

1 finding from 1 review

Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 129 participants
Very low